Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Talaris Therapeutics stock

Learn how to easily invest in Talaris Therapeutics stock.

Talaris Therapeutics, Inc

Talaris Therapeutics, Inc is a biotechnology business based in the US. Talaris Therapeutics shares (TALS) are listed on the NASDAQ and all prices are listed in US Dollars. Talaris Therapeutics employs 82 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Talaris Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TALS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Talaris Therapeutics stock price (NASDAQ: TALS)

Use our graph to track the performance of TALS stocks over time.

Talaris Therapeutics shares at a glance

Information last updated 2021-07-28.
52-week range$11.42 - $19.82
50-day moving average $14.84
200-day moving average $14.79
Wall St. target price$29.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Talaris Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Talaris Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Talaris Therapeutics financials

Gross profit TTM $0
Return on assets TTM -14.56%
Return on equity TTM -24.21%
Profit margin 0%
Book value N/A
Market capitalisation $600 million

TTM: trailing 12 months

Shorting Talaris Therapeutics shares

There are currently 591,241 Talaris Therapeutics shares held short by investors – that's known as Talaris Therapeutics's "short interest". This figure is 2322.5% up from 24,406 last month.

There are a few different ways that this level of interest in shorting Talaris Therapeutics shares can be evaluated.

Talaris Therapeutics's "short interest ratio" (SIR)

Talaris Therapeutics's "short interest ratio" (SIR) is the quantity of Talaris Therapeutics shares currently shorted divided by the average quantity of Talaris Therapeutics shares traded daily (recently around 148180.70175439). Talaris Therapeutics's SIR currently stands at 3.99. In other words for every 100,000 Talaris Therapeutics shares traded daily on the market, roughly 3990 shares are currently held short.

To gain some more context, you can compare Talaris Therapeutics's short interest ratio against those of similar companies.

However Talaris Therapeutics's short interest can also be evaluated against the total number of Talaris Therapeutics shares, or, against the total number of tradable Talaris Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Talaris Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Talaris Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0494% of the tradable shares (for every 100,000 tradable Talaris Therapeutics shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Talaris Therapeutics.

Find out more about how you can short Talaris Therapeutics stock.

Talaris Therapeutics share dividends

We're not expecting Talaris Therapeutics to pay a dividend over the next 12 months.

Talaris Therapeutics overview

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Stocks similar to Talaris Therapeutics

Talaris Therapeutics in the news

There are no recent company news

Frequently asked questions

What percentage of Talaris Therapeutics is owned by insiders or institutions?
Currently 13.427% of Talaris Therapeutics shares are held by insiders and 27.196% by institutions.
How many people work for Talaris Therapeutics?
Latest data suggests 82 work at Talaris Therapeutics.
When does the fiscal year end for Talaris Therapeutics?
Talaris Therapeutics's fiscal year ends in December.
Where is Talaris Therapeutics based?
Talaris Therapeutics's address is: 570 South Preston Street, Louisville, KY, United States, 40202

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site